These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 16298821

  • 21. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
    Culić S, Culić V, Armanda V, Kuljis D, Pesutić-Pisac V, Janković S.
    Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
    [Abstract] [Full Text] [Related]

  • 22. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM, Younes A.
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [Abstract] [Full Text] [Related]

  • 23. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.
    J Immunother; 2009 Aug; 32(6):622-31. PubMed ID: 19483647
    [Abstract] [Full Text] [Related]

  • 24. Rituximab therapy of B-cell neoplasms.
    Petryk M, Grossbard ML.
    Clin Lymphoma; 2000 Dec; 1(3):186-94; discussion 195-6. PubMed ID: 11707828
    [Abstract] [Full Text] [Related]

  • 25. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

  • 26. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
    Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA.
    J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
    [Abstract] [Full Text] [Related]

  • 27. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
    Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A.
    Blood; 1999 Oct 01; 94(7):2217-24. PubMed ID: 10498591
    [Abstract] [Full Text] [Related]

  • 28. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
    Errante D, Bernardi D, Bianco A, De Nardi S, Salvagno L.
    Ann Oncol; 2006 Nov 01; 17(11):1720-1. PubMed ID: 16731537
    [No Abstract] [Full Text] [Related]

  • 29. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA, Czerwinski DK, Levy R.
    Clin Cancer Res; 1999 Mar 01; 5(3):611-5. PubMed ID: 10100713
    [Abstract] [Full Text] [Related]

  • 30. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul 01; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 31. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA.
    Cancer Biother Radiopharm; 1999 Aug 01; 14(4):241-50. PubMed ID: 10850310
    [Abstract] [Full Text] [Related]

  • 32. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
    Pijuan L, Vicioso L, Bellosillo B, Ferrer MD, Baró T, Pedro C, Lloreta-Trull J, Munné A, Serrano S.
    Am J Surg Pathol; 2005 Oct 01; 29(10):1399-403. PubMed ID: 16160485
    [Abstract] [Full Text] [Related]

  • 33. Rituximab for HIV-associated lymphoma: weighing the benefits and risks.
    Spina M, Tirelli U.
    Curr Opin Oncol; 2005 Sep 01; 17(5):462-5. PubMed ID: 16093796
    [Abstract] [Full Text] [Related]

  • 34. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C, DeNardo G, Tobin E, DeNardo S.
    Cancer Biother Radiopharm; 2004 Oct 01; 19(5):545-61. PubMed ID: 15650447
    [Abstract] [Full Text] [Related]

  • 35. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec 01; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 36. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.
    Thomas DA, O'Brien S, Kantarjian HM.
    Hematol Oncol Clin North Am; 2009 Oct 01; 23(5):949-71, v. PubMed ID: 19825447
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 01; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 40. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG.
    Saikia TK, Menon H, Advani SH.
    Ann Oncol; 2001 Oct 01; 12(10):1493-4. PubMed ID: 11762825
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.